$19.00
Manufacturer: Ukraine
Antiviral agent that specifically suppresses influenza A and B viruses, including the highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1). According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes.
Therapeutic efficacy in influenza is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with influenza.
Description
Ingredients
active ingredient: umifenovir;
1 capsule contains umifenovir hydrochloride 200 mg;
excipients: potato starch, microcrystalline cellulose, calcium stearate, colloidal silicon dioxide, povidone, capsule shell contains titanium dioxide (E 171), gelatin.
Dosage form
Capsules.
Basic physical and chemical properties: white hard gelatin capsules. The contents of the capsules are a mixture containing granules and powder from white to white with a greenish-yellowish or yellowish tint. The presence of agglomerates of powder particles is allowed. It is allowed to apply the trademark of the enterprise – ZT on the capsule.
Pharmacotherapeutic group
Antiviral drugs for systemic use. Other antiviral drugs. ATX code J05A X13.
Pharmacodynamics
Antiviral agent that specifically suppresses influenza A and B viruses, including the highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1). According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes.
Therapeutic efficacy in influenza is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with influenza.
Arbivir forte (umifenovir) belongs to low-toxic drugs, does not have a negative effect on the human body when used in recommended doses.
Pharmacokinetics
The drug is rapidly absorbed in the digestive tract. The maximum concentration is reached 1.2 hours after taking a dose of 50 mg, 1.5 hours after taking a dose of 100 mg. The half-life is 17-21 hours. Approximately 40% is excreted unchanged in faeces (38.9%) and urine (0.12%). During the first day, 90% of the administered dose is excreted.
Indications
Prevention and treatment of influenza A and B.
Contraindications
Hypersensitivity to Arbivir forte (umifenovir).
Dosage and administration
Apply to adults. Take orally before meals. A single dose is 200 mg.
For prevention:
In direct contact with patients with influenza: 200 mg 1 time per day for 10-14 days.
During the influenza epidemic: 200 mg 2 times a week for 3 weeks.
For the treatment of influenza: 200 mg 4 times a day (every 6 hours) for 5 days.
The maximum daily dose is 800 mg.
Recent Reviews